ClinicalTrials.Veeva

Menu

The Gore SCAFFOLD Clinical Study

W.L. Gore & Associates logo

W.L. Gore & Associates

Status

Completed

Conditions

Carotid Artery Disease
Carotid Artery Stenosis

Treatments

Device: Carotid Artery Stenting

Study type

Interventional

Funder types

Industry

Identifiers

NCT01901874
GCS 10-08

Details and patient eligibility

About

Evaluate the safety and efficacy of the GORE® Carotid Stent for the treatment of carotid artery stenosis in patients at increased risk for adverse events from carotid endarterectomy

Full description

This is a prospective, multicenter, single-arm clinical study comparing outcomes with the GORE® Carotid Stent to a performance goal derived from carotid endarterectomy outcomes in high-surgical-risk patients.

Enrollment

312 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient is at least 18 years old at informed consent

  • Patient is willing and capable of complying with all study protocol requirements, including specified follow-up period and can be contacted by telephone.

  • Patient is willing to provide written informed consent prior to enrollment in study.

  • Patient is either:

    • Symptomatic with carotid stenosis ≥50% as determined by angiography using NASCET methodology. Symptomatic is defined as amaurosis fugax ipsilateral to the carotid lesion; Transient Ischemic Attack (TIA) or non-disabling stroke within 180 days of the procedure within the hemisphere supplied by the target vessel; OR
    • Asymptomatic with carotid stenosis ≥80% as determined by angiography using NASCET methodology
  • Patient must be considered high risk for adverse events during carotid endarterectomy

Note: Additional inclusion criteria may apply

Exclusion criteria

  • Patient has life expectancy of less than one year.
  • Patient is experiencing (or has experienced) an evolving, acute, or recent disabling stroke.
  • Patient has anticipated or potential sources of emboli (e.g. atrial fibrillation, known previously symptomatic patent foramen ovale (PFO), mechanical heart valve, or Deep Vein Thrombosis (DVT) treated within 6 months).
  • Patient has had an acute myocardial infarction within 72 hours prior to the index procedure.
  • Patient has a history of major, disabling ipsilateral stroke with residual deficit that may confound the neurological subject assessments.
  • Patient has known severe carotid stenosis contralateral to the target lesion requiring treatment within 30 days following the index procedure.

Note: Additional exclusion criteria may apply

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

312 participants in 1 patient group

Carotid Artery Stenting
Experimental group
Description:
Carotid Artery Stenting with the GORE® Carotid Stent
Treatment:
Device: Carotid Artery Stenting

Trial documents
2

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems